Vir Biotechnology
Open
$8.62
Prev. Close
$8.63
High
$8.63
Low
$8.60
Market Snapshot
$1.2B
-2.7
-3.82
$74.21M
367
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 367 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Recently from Cashu
Vir Biotechnology to Announce Q4 Results and Corporate Update on February 26, 2025
Vir Biotechnology Highlights Upcoming Corporate Update and Q4 Financial Results Vir Biotechnology, Inc. prepares to deliver a significant corporate update on February 26, 2025, alongside its financial…
Vir Biotechnology's VIR-5818 Shows Promise in Cancer Treatment with Phase 1 Data
Vir Biotechnology Reveals Promising Phase 1 Data for Novel T-Cell Engagers in Cancer Treatment Vir Biotechnology, Inc. has recently unveiled initial Phase 1 data for its innovative dual-masked T-cell…
Vir Biotechnology Showcases Innovative Treatments at 43rd J.P. Morgan Healthcare Conference
Vir Biotechnology's Commitment to Innovative Treatments Highlighted at Upcoming Conference Vir Biotechnology Inc. is poised to showcase its commitment to advancing transformative medical solutions dur…
Vir Biotechnology Secures Breakthrough Designations for Chronic Hepatitis Delta Treatments
Vir Biotechnology Advances Chronic Hepatitis Delta Treatments with Regulatory Designations Vir Biotechnology, Inc. has achieved significant milestones in the development of its therapies, tobevibart a…